Evidence map›Paper›PMID 39479474›Full record

ArticleCase reports in hematology2024

Four Cases of Myeloproliferative Disorders Associated With Down Syndrome: Distinguishing ML-DS From TAM-DS: Distinguishing TAM-DS and ML-DS: Report of 4 Cases.

Kévin Boumeghar, Sylvie Daliphard, Nimrod Buchbinder, Catherine Boutet, Dominique Penther, Pascaline Etancelin, Julien Bourgain, Gérard Buchonnet, Elsa Bera, Victor Bobée

Abstract readCase Reports
In one paragraph

Article in Case reports in hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kévin BoumegharRouen University Hospital, Department of Biological Hematology, Rouen 76000, France.
Sylvie DaliphardRouen University Hospital, Department of Biological Hematology, Rouen 76000, France.
Nimrod BuchbinderRouen University Hospital, Department of Pediatric Hematology, Rouen 76000, France.
Catherine BoutetRouen University Hospital, Department of Biological Hematology, Rouen 76000, France.
Dominique PentherCentre Henri Becquerel, Department of Genetic Oncology, Rouen 76000, France.
Pascaline EtancelinCentre Henri Becquerel, Department of Genetic Oncology, Rouen 76000, France.
Julien BourgainRouen University Hospital, Department of Biological Hematology, Rouen 76000, France.
Gérard BuchonnetRouen University Hospital, Department of Biological Hematology, Rouen 76000, France.
Elsa BeraRouen University Hospital, Department of Biological Hematology, Rouen 76000, France.
Victor BobéeRouen University Hospital, Department of Biological Hematology, Rouen 76000, France.ORCID https://orcid.org/0000-0002-9357-4542

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Down syndrome (DS) is defined by an extra copy of chromosome 21 and confers an increased susceptibility to hematological disorders. Transient abnormal myelopoiesis (TAM) and myeloid-leukemia associated with Down syndrome (ML-DS) are two conditions that need to be accurately diagnosed to provide appropriate management. Both TAM and ML-DS are characterized by proliferation of megakaryoblasts carrying a mutation in the GATA1 gene. Here, we report four cases with educational significance, highlighting typical diagnostic features that facilitate the differentiation between these two conditions, thereby assisting clinicians and medical laboratory professionals in effectively managing and monitoring these patients.

Indexed as

down syndromeGATA1ML-DSTAM-DStransient abnormal myelopoiesis

Identifiers

PMID39479474
PMCPMC11524717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.